Security
Fulcrum Therapeutics, Inc. Common Stock · FULC
FULCNASDAQCommon stockCurrentCIK 1680581Updated Oct 29, 2026
FULC price & chart
Loading TradingView…
NASDAQ:FULC on TradingView ↗About the company
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with rare hematological disorders. Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of genetically defined diseases. For more information, visit www.fulcrumtx.com and follow it on X (@FulcrumTx) and LinkedIn.
In the news
$HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the Merger - HOWL, HZO, TYFG and FULC ↗
Fulcrum Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their Losses ↗
FULC INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Fulcrum Therapeutics, Inc. ↗
Recent filings
S-4/A filing
SCHEDULE 13G/A - filed by BANK OF AMERICA CORP /DE/ regarding Fulcrum Therapeutics, Inc.
S-4/A filing
S-4/A filing
144 filing
Show 5 more recent filings
S-4 filing
425 filing
425 filing
425 filing
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Changes in Control of Registrant · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Items 1.01, 3.02, 5.01, 5.02, 7.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 214,858,000Source | 279,008,000Source | 323,952,000Source | 228,838,000Source | 294,256,000Source | 346,770,000Source | 242,649,000Source | 232,588,000Source | 366,284,000Source | 260,718,000Source | 257,694,000Source | 226,685,000Source |
| Property, Plant and Equipment, NetUSD | 3,171,000Source | 4,218,000Source | 0Source | 3,269,000Source | 4,408,000Source | 2,494,000Source | 3,547,000Source | 4,765,000Source | 2,824,000Source | 3,900,000Source | 5,216,000Source | 6,906,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 47,078,000Source | 72,630,000Source | 48,466,000Source | 42,588,000Source | 86,702,000Source | 50,261,000Source | 42,178,000Source | 39,949,000Source | 197,533,000Source | 58,212,000Source | 25,563,000Source | 35,098,000Source |
| Assets, CurrentUSD | 205,863,000Source | 267,489,000Source | 322,851,000Source | 219,373,000Source | 280,286,000Source | 338,669,000Source | 232,556,000Source | 217,952,000Source | 357,480,000Source | 249,923,000Source | 242,199,000Source | 207,519,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 5,218,000Source | 6,599,000Source | 4,011,000Source | 5,262,000Source | 4,175,000Source | 5,353,000Source | 4,974,000Source | 4,638,000Source | 5,174,000Source | 6,806,000Source | 5,441,000Source | 4,369,000Source |
| Operating Lease, Right-of-Use AssetUSD | 4,614,000Source | 6,024,000Source | 0Source | 4,979,000Source | 6,357,000Source | 3,860,000Source | 5,335,000Source | 6,682,000Source | 4,241,000Source | 5,684,000Source | 7,176,000Source | 9,063,000Source |
| Other Assets, NoncurrentUSD | 9,000Source | 76,000Source | 9,000Source | 12,000Source | 1,989,000Source | 546,000Source | 10,000Source | 1,988,000Source | 538,000Source | 10,000Source | 2,011,000Source | 2,105,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 16,492,000Source | 21,717,000Source | 13,255,000Source | 14,460,000Source | 20,466,000Source | 13,467,000Source | 14,163,000Source | 18,996,000Source | 17,284,000Source | 17,684,000Source | 22,501,000Source | 27,743,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | — |
| Common Stock, Value, IssuedUSD | 54,000Source | 54,000Source | 76,000Source | 54,000Source | 62,000Source | 67,000Source | 54,000Source | 62,000Source | 67,000Source | 54,000Source | 62,000Source | 52,000Source |
| Retained Earnings (Accumulated Deficit)USD | -573,944,000Source | -502,830,000Source | -639,348,000Source | -554,349,000Source | -481,134,000Source | -613,169,000Source | -537,053,000Source | -536,543,000Source | -594,278,000Source | -519,398,000Source | -509,673,000Source | -412,338,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 241,000Source | 379,000Source | -567,000Source | 82,000Source | -366,000Source | -513,000Source | 70,000Source | -434,000Source | 174,000Source | 130,000Source | -136,000Source | -797,000Source |
| Stockholders' Equity Attributable to ParentUSD | 198,366,000Source | 257,291,000Source | 310,697,000Source | 214,378,000Source | 273,790,000Source | 333,303,000Source | 228,486,000Source | 213,592,000Source | 349,000,000Source | 243,034,000Source | 235,193,000Source | 198,942,000Source |
| Additional Paid in Capital, Common StockUSD | 772,015,000Source | 759,688,000Source | 950,536,000Source | 768,591,000Source | 755,228,000Source | 946,918,000Source | 765,415,000Source | 750,507,000Source | 943,037,000Source | 762,248,000Source | 744,940,000Source | 612,025,000Source |
| Liabilities and EquityUSD | 214,858,000Source | 279,008,000Source | 323,952,000Source | 228,838,000Source | 294,256,000Source | 346,770,000Source | 242,649,000Source | 232,588,000Source | 366,284,000Source | 260,718,000Source | 257,694,000Source | 226,685,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 11,632,000Source | 14,509,000Source | 10,298,000Source | 8,985,000Source | 12,699,000Source | 9,864,000Source | 8,100,000Source | 10,694,000Source | 13,048,000Source | 11,044,000Source | 13,675,000Source | 16,725,000Source |
| Operating Lease, Liability, CurrentUSD | 2,348,000Source | 2,134,000Source | 2,518,000Source | 2,293,000Source | 2,082,000Source | 2,461,000Source | 2,239,000Source | 2,032,000Source | 2,404,000Source | 2,186,000Source | 2,192,000Source | 2,602,000Source |
| Accounts Payable, CurrentUSD | 2,856,000Source | 4,041,000Source | 3,425,000Source | 1,751,000Source | 3,584,000Source | 2,450,000Source | 1,507,000Source | 3,857,000Source | 1,592,000Source | 1,164,000Source | 2,757,000Source | 3,638,000Source |
| Operating Lease, Liability, NoncurrentUSD | 4,663,000Source | 7,011,000Source | 2,760,000Source | 5,278,000Source | 7,570,000Source | 3,406,000Source | 5,866,000Source | 8,105,000Source | 4,039,000Source | 6,443,000Source | 8,629,000Source | 10,821,000Source |
| Other Liabilities, NoncurrentUSD | 197,000Source | 197,000Source | 197,000Source | 197,000Source | 197,000Source | 197,000Source | 197,000Source | 197,000Source | 197,000Source | 197,000Source | 197,000Source | 197,000Source |
| Additional Financial Items | ||||||||||||
| Deferred Revenue, CurrentUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 934,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -18,891,000Source | -17,655,000Source | -74,880,000Source | -9,725,000Source | -97,335,000Source | -109,872,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | 3,360,000Source | 3,817,000Source | 3,271,000Source | 2,875,000Source | 3,860,000Source | 3,167,000Source | 12,468,000Source | 14,554,000Source | 14,802,000Source | 13,350,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 0Source | -1,117,000Source | -2,096,000Source | 1,559,000Source | 308,000Source | -908,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 858,000Source | 343,000Source | 428,000Source | -1,593,000Source | -853,000Source | -1,176,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -18,750,000Source | -15,257,000Source | -60,065,000Source | -2,218,000Source | -90,965,000Source | -97,050,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -128,210,000Source | -777,000Source | 30,719,000Source | 32,230,000Source | -36,692,000Source | 12,413,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 8,000Source | 0Source | 314,000Source | 278,000Source | 508,000Source | 1,963,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -312,000Source | 0Source | 168,667,000Source | 2,746,000Source | 118,122,000Source | 84,323,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -147,272,000Source | -16,034,000Source | 139,321,000Source | 32,758,000Source | -9,535,000Source | -314,000Source |
| Additional Financial Items | ||||||||||||
| DepreciationUSD | — | — | 300,000Source | 400,000Source | 200,000Source | 300,000Source | 338,000Source | 353,000Source | 1,390,000Source | 1,593,000Source | 2,172,000Source | 2,414,000Source |
| General and Administrative ExpenseUSD | — | — | 7,562,000Source | 8,424,000Source | 7,462,000Source | 6,828,000Source | 8,102,000Source | 6,999,000Source | 28,666,000Source | 36,448,000Source | 41,668,000Source | 41,694,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -19,595,000Source | -21,696,000Source | -26,179,000Source | -17,296,000Source | -18,891,000Source | -17,655,000Source | -74,880,000Source | -9,725,000Source | -97,335,000Source | -109,871,000Source |
| Operating ExpensesUSD | — | — | 21,858,000Source | 25,126,000Source | 29,310,000Source | 19,815,000Source | 22,186,000Source | 20,403,000Source | 84,769,000Source | 101,897,000Source | 113,469,000Source | 118,903,000Source |
| Operating Lease, ExpenseUSD | — | — | 500,000Source | 500,000Source | 300,000Source | 500,000Source | 500,000Source | 500,000Source | 1,900,000Source | 1,900,000Source | 1,900,000Source | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 21,000Source | 0Source | 4,167,000Source | 2,746,000Source | 777,000Source | 3,519,000Source |
| Restructuring CostsUSD | — | — | — | — | — | — | — | 0Source | 0Source | 2,063,000Source | — | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 0Source | 0Source | — | 0Source | — | — | 0Source | 80,000,000Source | 2,805,000Source | 6,342,000Source |
| Operating Lease, Impairment Loss | — | — | — | — | —Source | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -21,858,000Source | -25,126,000Source | -29,310,000Source | -19,815,000Source | -22,186,000Source | -20,403,000Source | -84,769,000Source | -21,897,000Source | -110,664,000Source | -112,561,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -19,595,000Source | -21,696,000Source | -26,179,000Source | -17,296,000Source | -18,891,000Source | -17,655,000Source | -74,880,000Source | -9,725,000Source | -97,335,000Source | -109,871,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.31Source | -0.35Source | -0.34Source | -0.28Source | -0.25Source | -0.28Source | -1.18Source | -0.16Source | -1.59Source | -2.44Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.31Source | -0.35Source | -0.34Source | -0.28Source | -0.25Source | -0.28Source | -1.18Source | -0.16Source | -1.59Source | -2.44Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 62,597,000Source | 62,409,000Source | 76,264,000Source | 62,544,000Source | 76,215,000Source | 62,479,000Source | 63,355Source | 61,984Source | 61,310Source | 44,991Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 62,597,000Source | 62,409,000Source | 76,264,000Source | 62,544,000Source | 76,215,000Source | 62,479,000Source | 63,355Source | 61,984Source | 61,310Source | 44,991Source |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 7,562,000Source | 8,424,000Source | 7,462,000Source | 6,828,000Source | 8,102,000Source | 6,999,000Source | 28,666,000Source | 36,448,000Source | 41,668,000Source | 41,694,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | 2,263,000Source | 3,430,000Source | 3,131,000Source | 2,519,000Source | 3,295,000Source | 2,748,000Source | 9,889,000Source | 12,172,000Source | 13,329,000Source | 2,690,000Source |
| Operating ExpensesUSD | — | — | 21,858,000Source | 25,126,000Source | 29,310,000Source | 19,815,000Source | 22,186,000Source | 20,403,000Source | 84,769,000Source | 101,897,000Source | 113,469,000Source | 118,903,000Source |
| Operating Lease, ExpenseUSD | — | — | 500,000Source | 500,000Source | 300,000Source | 500,000Source | 500,000Source | 500,000Source | 1,900,000Source | 1,900,000Source | 1,900,000Source | — |
| Research and Development ExpenseUSD | — | — | 14,296,000Source | 14,639,000Source | 12,444,000Source | 12,987,000Source | 14,084,000Source | 13,404,000Source | 56,103,000Source | 63,386,000Source | 71,801,000Source | 76,782,000Source |
| Restructuring and Related Cost, Incurred CostUSD | — | — | 0Source | 2,063,000Source | 4,318,000Source | 0Source | — | — | 0Source | 2,063,000Source | 0Source | 427,000Source |
| Restructuring CostsUSD | — | — | — | — | — | — | — | 0Source | 0Source | 2,063,000Source | — | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 0Source | 0Source | — | 0Source | — | — | 0Source | 80,000,000Source | 2,805,000Source | 6,342,000Source |
Offerings
Registration 333-298705
Filing attachments
d127837dex991.htm · S-4 · 2026-09-02
Exhibit 99.1 CONSENT TO BE NAMED AS A DIRECTOR NOMINEE In connection with the filing by Fulcrum Therapeutics, Inc., a Delaware corporation (the “Company”), of the Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement, and any amendments and supplements thereto, as a…
Read attachment ↗d127837dex992.htm · S-4 · 2026-09-02
Exhibit 99.2 CONSENT TO BE NAMED AS A DIRECTOR NOMINEE In connection with the filing by Fulcrum Therapeutics, Inc., a Delaware corporation (the “Company”), of the Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement, and any amendments and supplements thereto, as a…
Read attachment ↗d136791dex991.htm · 8-K · 2026-08-17
EX-99.1 8 d136791dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies Combined company to operate as Slate Medicines and focus on advancing Slate’s portfolio of next-generation migraine therapeutics Slate’s lead product candidate, SLTE-1009, is a clinical stage, potentially best-in-class subcutaneous anti-PACAP/VIP monoclonal antibody for the preventative treatment of migraine Concurrent…
Read attachment ↗d136791dex992.htm · 8-K · 2026-08-17
EX-99.2 9 d136791dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 Slate Medicines Corporate Overview August 17, 2026 Disclaimers This presentation (this “Presentation”) has been prepared by Slate Medicines, Inc. (the “Company” or “Slate”) for informational purposes only and shall not form the basis for or be relied on in connection with any investment decision with respect to the Company, Fulcrum Therapeutics, Inc. (“Fulcrum”) or the combined company. This Presentation has been prepared by the Comp…
Read attachment ↗fulc-ex99_1.htm · 8-K · 2026-06-01
EX-99.1 2 fulc-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review ― Decision follows FDA feedback regarding the implications of the secondary malignancies observed with Tazverik® (tazemetostat) and the product’s subsequent global withdrawal on the benefit-risk profile of pociredir in sickle cell disease (SCD) ― ― Company to explore strategic alternatives to maximize stockhol…
Read attachment ↗fulc-ex99_1.htm · 8-K · 2026-04-27
EX-99.1 2 fulc-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026 ― Presented positive clinical data for pociredir, demonstrating robust and rapid fetal hemoglobin (HbF) induction, improvements in markers of hemolysis and anemia, and encouraging trends in vaso-occlusive crisis (VOC) reduction ― ― Fulcrum plans to initiate a potential registration-enabling trial in the second half of 2026 ― ― Dos…
Read attachment ↗